TScan Therapeutics (TCRX) Free Cash Flow (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Free Cash Flow of -$24.3 million for Q1 2026, up 37.75% year-over-year from -$17.7 million in Q1 2025, and up 23.81% quarter-over-quarter from -$32.0 million in Q4 2025.
TScan Therapeutics (TCRX) Free Cash Flow (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Free Cash Flow for 7 consecutive years, with -$24.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 37.75% year-over-year to -$24.3 million; the TTM figure through Mar 2026 stood at -$120.6 million (up 2.61% YoY), while the FY2025 annual figure was -$135.3 million, down 18.04% from the prior year.
- Free Cash Flow rose to -$24.3 million in Q1 2026 per TCRX's latest filing, from -$32.0 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $7.8 million in Q3 2023 and bottomed at -$39.1 million in Q1 2025.
- Historically, Free Cash Flow has averaged -$23.7 million across 5 years, with a median of -$24.3 million in 2026.
- Annual changes were most pronounced in 2023 — Free Cash Flow jumped 151.23% — and 2024, when it plunged 477.37%.
- TScan Therapeutics' Free Cash Flow stood at -$15.9 million in 2022, then plunged by 49.38% to -$23.7 million in 2023, then decreased by 19.29% to -$28.3 million in 2024, then declined by 12.92% to -$32.0 million in 2025, then climbed by 23.81% to -$24.3 million in 2026.
- Business Quant data shows TCRX's Free Cash Flow at -$24.3 million in Q1 2026, -$32.0 million in Q4 2025, and -$31.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | -28.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.03 Mn |
| Jun 30, 2026 | -28.03 Mn |
| Mar 31, 2026 | -24.35 Mn |
| Mar 31, 2026 | -24.35 Mn |
| Dec 31, 2025 | -31.96 Mn |
| Dec 31, 2025 | -31.96 Mn |
| Sep 30, 2025 | -31.59 Mn |
| Sep 30, 2025 | -31.59 Mn |
| Jun 30, 2025 | -32.66 Mn |
| Jun 30, 2025 | -32.66 Mn |
| Mar 31, 2025 | -39.12 Mn |
| Mar 31, 2025 | -39.12 Mn |
| Dec 31, 2024 | -28.30 Mn |
| Dec 31, 2024 | -28.30 Mn |
| Sep 30, 2024 | -29.29 Mn |
| Sep 30, 2024 | -29.29 Mn |
| Jun 30, 2024 | -27.09 Mn |
| Jun 30, 2024 | -27.09 Mn |
| Mar 31, 2024 | -29.97 Mn |
| Mar 31, 2024 | -29.97 Mn |